■中药(TCM)已成为治疗非小细胞肺癌的潜在辅助疗法。必须在各种口服TCM之间进行更直接的比较研究。
■该网络荟萃分析评估了七种口服TCM联合化疗治疗NSCLC的有效性和安全性。
■分析包括子龙津,班茂,红斗山,华昌苏,康莱特,西黄,和平消中药。随机对照试验(RCT)从以下数据库中确定:中国国家基础设施,万方,PubMed,Embase,和Cochrane图书馆到2023年4月。两名研究人员独立提取数据。
■纳入68个随机对照试验(5,099名患者)。与化疗相比,板毛胶囊[比值比(OR)=2.69,95%置信区间(CI)1.96~3.69)]和华蟾片[OR=2.35,95CI(1.81,3.05)]在疾病控制率提高方面排名前两位。提高客观有效率的两种主要中药分别为斑茅胶囊[OR=3.49,95CI(2.17,5.60)]和紫龙金片[OR=2.62,95CI(1.92,3.57)]。紫龙金片[OR=3.47,95CI(2.14,5.63)]和华蟾片[OR=3.30,95CI(1.65,6.60)]在提高Karnofsky绩效状态方面排名前两位。红豆山胶囊(SUCRA=18.8%)和板毛胶囊(SUCRA=19.8%)在降低胃肠道毒性方面排名前两位。紫龙金片(SUCRA=18.9%)和半毛胶囊(SUCRA=26.6%)是降低肝肾毒性的前两种。红豆山胶囊(SUCRA=15.7%)和华蟾素片(SUCRA=16.8%)在减少血小板减少方面排名前两位。半毛胶囊(SUCRA=14.3%)和紫龙金片(SUCRA=26.3%)是白细胞减少的前两名。
■与单独的铂类化疗相比,口服TCM与铂类化疗联合治疗NSCLC显示出更好的疗效。
UNASSIGNED: Traditional Chinese medicines (TCMs) have emerged as potential adjuvant therapies to treat non-small cell lung cancer. More direct comparative studies must be conducted among various oral TCMs.
UNASSIGNED: This network meta-analysis evaluates the efficacy and safety of seven oral TCMs combined with chemotherapy in treating NSCLC.
UNASSIGNED: The analysis included Zilongjin, Banmao, Hongdoushan, Huachansu, Kanglaite, Xihuang, and Pingxiao TCMs. Randomized-controlled trials (RCTs) were identified from the following databases: China National Infrastructure, Wanfang, PubMed, Embase, and the Cochrane Library up to April 2023. Two researchers independently extracted data.
UNASSIGNED: Sixty-eight RCTs (5,099 patients) were included. Compared to chemotherapy, Banmao capsules [odds ratio (OR) = 2.69, 95% confidence interval (CI) 1.96-3.69)] and Huachansu tablets [OR = 2.35, 95%CI (1.81, 3.05)] ranked in the top two in terms of increasing disease control rate. The two main TCMs to improve the objective response rate were Banmao capsules [OR = 3.49, 95%CI (2.17, 5.60)] and Zilongjin tablets [OR = 2.62, 95%CI (1.92, 3.57)]. Zilongjin tablets [OR = 3.47, 95%CI (2.14, 5.63)] and Huachansu tablets [OR = 3.30, 95%CI (1.65, 6.60)] were ranked as the top two in improving Karnofsky performance status. Hongdoushan capsules (SUCRA = 18.8%) and Banmao capsules (SUCRA = 19.8%) were the top two in reducing gastrointestinal toxicity. Zilongjin tablets (SUCRA = 18.9%) and Banmao capsules (SUCRA = 26.6%) were the top two to reduce liver and kidney toxicity. Hongdoushan capsules (SUCRA = 15.7%) and Huachansu tablets (SUCRA = 16.8%) ranked the top two in reducing thrombocytopenia. Banmao capsules (SUCRA = 14.3%) and Zilongjin tablets (SUCRA = 26.3%) were the top two decreasing leukopenia.
UNASSIGNED: Combining oral TCMs with platinum-based chemotherapy has shown superior efficacy compared to platinum-based chemotherapy alone in treating NSCLC.